Stockhub

Werewolf Therapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 August 2022

14 August 2022

29 July 2022

  • curprev 15:1515:15, 29 July 2022‎ Chris talk contribs‎ 956 bytes +956‎ Created page with "Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE mole..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Werewolf_Therapeutics,_Inc.’